Regulation of tyrosine hydroxylase promoter activity by the von Hippel-Lindau tumor suppressor protein and hypoxia-inducible transcription factors

Journal of Neurochemistry

Volumn 85, Issue 2, 2003, Pages 483-491

  Schnell, Phillip O ^a   Ignacak, Monika L ^a   Bauer, Amy L ^a   Striet, Justin B ^a   Paulding, Waltke R ^b   Czyzyk Krzeska, Maria F ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b XAVIER UNIVERSITY   (United States)

Author keywords

Gene transcription; Hypoxia; Hypoxia inducible factor; Tyrosine hydroxylase; Von Hippel Lindau tumor suppressor protein

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; TUMOR SUPPRESSOR PROTEIN; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

ANIMAL CELL; ARTICLE; CAROTID BODY; CATECHOLAMINE SYNTHESIS; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE INDUCTION; GENE REPRESSION; HYPOXIA; NONHUMAN; PHEOCHROMOCYTOMA CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN INTERACTION; RAT; REPORTER GENE;

ANIMALIA;

EID: 0037389490     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2003.01696.x     Document Type: Article

References (43)

1. Atuk N. O., Stolle C., Owen J. A. Jr, Carpenter J. T. and Vance M. L. (1998) Pheochromocytoma in von Hippel-Lindau disease: clinical presentation and mutation analysis in a large multigenerational kindred. J. Clin. Endocrinol. Metab. 83, 117-120.
2. Bauer A. L., Paulding W. R., Striet J. B., Schnell P. O. and Czyzyk-Krzeska M. F. (2002) Endogenous rat von Hippel-Lindau tumor suppressor protein regulates catecholaminergic phenotype in PC12 cells. Cancer Res. 62, 1682-1687.
3. Beitner-Johnson D. and Millhorn D. E. (1998) Hypoxia induces phosphorylation of the cyclic AMP response element-binding protein by a novel signaling mechanism. J. Biol. Chem. 273, 19834-19839.
4. Bender B. U., Altehofer C., Januszewicz A., Gartner R., Schmidt H., Hoffman M. M., Heidemann P. H. and Neumann H. P. H. (1997) Functioning thoracic paraganglioma: association with von Hippel-Lindau syndrome. J. Clin. Endocrinol. Metab. 82, 3356-3360.
5. Bergman D. B., Halaban R., van Gool A. J., Henning K. A., Friedberg E. C. and Warren S. L. (1996) UV-induced ubiquitination of RNA polymerase II: a novel modification deficient in Cockayne syndrome cells. Proc. Natl Acad. Sci. USA 93, 11586-11590.
6. Best J. A. and Tank A. W. (1998) The THCRE2 site in the rat tyrosine hydroxylase gene promoter is responsive to phorbol esters. Neurosci. Lett. 258, 131-134.
7. Bruick R. K. and McKnight S. L. (2001) A conserved family ofprolyl-4-hydroxylases that modify HIF. Science 294, 1337-1340.
8. Clifford S. C., Cockman M. E., Smallwood A. C., Mole D. R., Woodward E. R., Maxwell P. H., Ratcliffe P. J. and Maher E. R. (2001) Contrasting effects on HIF1a regulation by disease-causing pVHL mutations correlate with patterns of tumorigenesis in von Hippel-Lindau disease. Hum. Mol. Genet. 10, 1029-1038.
9. Cockman M. E., Masson N., Mole D. R., Jaakkola P., Chang G.-W., Clifford S. C., Maher E. R., Pugh C. W., Ratcliffe P. J. and Maxwell P. H. (2000) Hypoxia inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 275, 25733-25741.
10. Crossey P. A., Eng C., Ginalska-Malinowska M., Lennard T. W. J., Wheeler D. D., Ponder B. A. J. and Maher E. R. (1995) Molecular genetic diagnosis of von Hippel-Lindau disease in familial pheochromocytoma. J. Med. Genet. 32, 885-886.
11. Czyzyk-Krzeska M. F., Bayliss D. A., Lawson E. E. and Millhorn D. E. (1992) Regulation of tyrosine hydroxylase gene expression in the rat carotid body by hypoxia. J. Neurochem. 58, 1538-1546.
12. Czyzyk-Krzeska M. F., Furnari B. A., Lawson E. E. and Millhorn D. E. (1994) Hypoxia increases rate of transcription and stability of tyrosine hydroxylase mRNA in pheochromocytoma (PC12) cells. J. Biol. Chem. 269, 760-764.
13. Eisenhofer G., Walther M. M., Huynh T.-T., Li S.-T., Bornstein S. R., Vortmeyer A., Mannelli M., Goldstein D. S., Linehan W. M., Lenders J. W. M. and Pacak K. (2001) Pheochromocytomas in von Hippel-Lindau syndrome and mutiple endocrine neoplasia type 2 display distict biochemical and clinical phenotypes. J. Cell. Endocrinol. Metab. 86, 1999-2008.
14. Feldman J. M., Blalock J. A., Zem R. T. and Wells S. A. (1979) The relationship between enzyme activity and the catecholamine content and secretion of pheochromocytomas. J. Cell. Endocrinol. Metab. 49, 445-451.
15. Gnarra J., Zhou S., Merrill M. J., Wagner J. R., Krumm A., Papavassiliou E., Oldfield E. H., Klausner R. D. and Linehan W. M. (1996) Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc. Natl Acad. Sci. USA 93, 10589-10594.
16. Gross D. J., Avishi N., Meiner V., Filon D., Zbar B. and Abeliovich D. (1996) Familiar pheochromocytoma associated with a novel mutation in the von Hippel-Lindau gene. J. Clin. Endocrinol. Metab. 81, 147-149.
17. Hoffman M. A., Ohh M., Yang H., Klco J. M., Ivan M. and Kaelin W. G. Jr (2001) von Hippel-Lindau protein mutanats linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum. Mol. Genet. 10, 1019-1027.
18. Iliopoulos O., Kibel A., Gray S. and Kaelin W. G. Jr (1995) Tumor suppression by the human von Hippel-Lindau gene product. Nature Med. 1, 822-826.
19. Iliopoulos O., Levy A. P., Jiang C., Kaelin W. G. Jr and Goldberg M. A. (1996) Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl Acad. Sci. USA 93, 10595-10599.
20. Isobe K., Nakai T., Yukimasa N, Nanmoku T., Takekoshi K. and Nomura F. (1998) Expression of mRNA coding for four catecholamine-synthesizing enzymes in human adrenal pheochromocytoma. Eur. J. Endocrinol. 138, 383-387.
21. 2 sensing. Science 292, 464-468.
22. 2-regulated prolyl hydroxylation. Science 292, 468-472.
23. Kamura T., Sato S., Iwai K., Czyzyk-Krzeska M. F., Conaway R. C. and Conaway J. W. (2000) Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc. Natl Acad. Sci. USA 97, 10430-10435.
24. Kenady D. E., McGrath P. C., Sloan D. A. and Schwartz R. W. (1997) Diagnosis and management of pheochromocytoma. Curr. Opin. Oncol. 9, 61-67.
25. Kroll S. L., Paulding W. R., Schnell P. O., Barton M. C., Conaway J. W., Conaway R. C. and Czyzyk-Krzeska M. F. (1999) von Hippel Lindau protein induces hypoxia-regulated arrest of tyrosine hydroxylase transcript elongation in pheochromocytoma cells. J. Biol. Chem. 274, 30109-30114.
26. Latif E, Tory K., Gnarra J., Yao M., Duh F. M., Orcutt M. L., Stackhouse T., Kuzmin I., Modi W., Geil L., Schmidt L., Zhou F., Li H., Wei M. H., Chen F., Glenn G., Choyke P., Walther M. M., Weng Y., Duan D.-S. R., Dean M., Glavac D., Richards F. M., Crossey P. A., Ferguson-Smith M. A., Le Paslier D., Chumakov I., Cohen D., Chinault A. C., Maher E. R., Linehan W. M., Zbar B. and Lerman M. I. (1993) Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260, 1317-1320.
27. Lehnert H. (1998) Regulation of catecholamine synthesizing enzyme gene expression in human pheochromocytoma. Eur J. Endocrinol. 138, 363-367.
28. Los M., Aarsman C. J., Terpstram L., Wittebol-Postm D., Lips C. J., Blijham G. H. and Voest E. E. (1997) Elevated ocular levels of vascular endothelial growth factor in patients with von Hippel-Lindau disease. Ann. Oncol. 8, 1015-1022.
29. Maher E. R. and Kaelin W. G. Jr (1997) Von Hippel-Lindau disease. Rev. Mol. Med. 76, 381-397.
30. Mishra R. R., Adhikary G., Simonson M. S., Chemiack N. S. and Prabhakar N. R. (1998) Role of c-fos in hypoxia-induced AP-1 cis-element activity and tyrosine hydroxylase gene expression. Mol. Brain Res. 59, 74-83.
31. 2-responsive sequences on the tyrosine hydroxylase gene. J. Biol. Chem. 270, 23774-23779.
32. Ohh M., Park C. W., Ivan M., Hoffman M. A., Kim T. Y., Huang L. E., Pavletich N., Chau V. and Kaelin W. G. (2000) Ubiquitination of hypoxia-inducible factor requires direct binding to the betadomain of the von Hippel-Lindau protein. Nature Cell Biol. 2, 423-427.
33. Paulding W. R. and Czyzyk-Krzeska M. F. (1999) Regulation of tyrosine hydroxylase mRNA stability by protein-binding, pyrimidine-rich sequence in the 3′-untranslated region. J. Biol. Chem. 274, 2532-2538.
34. Ravi R., Mookerjee B., Bhujwalla Z. M., Sutter C. H., Artemov D., Zeng Q., Dillehay L. E., Madan A., Semenza G. L. and Bedi A. (2000) Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 14, 34-44.
35. Rodriguez-Cuveas S., Lopez-Garza J. and Labastida-Almendaro S. (1998) Carotid body tumors in inhabitants of altitudes higher than 2000 meters above sea level. Head Neck 20, 374-378.
36. Semenza G. L. (2000) HIF-1: mediator of physiological and pathophysiological response to hypoxia. J. Appl. Physiol. 88, 1474-1480.
37. Tian H., Hammer R. E., Matsiumoto A. M., Russell D. W. and McKnight S. L. (1998) The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev. 12, 3320-3324.
38. Tomita N., Moriguchi A., Yamasaki K., Taniyama Y., Nashiya M., Yoshida M., Yao M., Higaki J. and Ogihara T. (2001) A family with von Hippel-Lindau disease revealed by pheochromocytoma. Hypertens. Res. 24, 445-450.
39. Walther M. M., Reiter R., Keiser H. R., Choyke P. L., Venzon D., Hurley K., Gnarra J. R., Reynolds J. C., Glenn G. M., Zbar B. and Linehan W. M. (1999) Clinical and genetic characterization of pheochromocytoma in von Hippel Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma. J. Urol. 162, 659-665.
40. Yu F., White S. B., Zhao Q. and Lee F. S. (2001) HIF1a binding to VHL is regulated by stimulus sensitive proline hydroxylation. Proc. Natl Acad. Sci. USA 98, 9630-9635.
41. Wizigmann-Voos S., Breier G., Risau W. and Plate K. H. (1995) Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res. 55, 1358-1364.
42. Yang H. and Kaelin W. G. Jr (2001) Molecular pathogenesis of the von Hippel-Lindau hereditary cancer syndrome: implication for oxygen sensing. Cell Growth Diff 12, 447-455.
43. Zanelli M. and Van der Walt J. D. (1996) Carotid body paraganglioma in von Hippel-Lindau disease. Histopathology 29, 178-181.